First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

Recruiting now · Phase 1

Conditions studied: Solid Tumors, Sarcoma

In brief

This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.

Key facts

Study ID

NCT06644755

Run by

Daiichi Sankyo

People needed

150

Starts

2024-11-14

Expected to finish

2028-11-30

Last updated by the study team

2025-07-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
• David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
• Sarah Cannon Research Institute — Nashville, Tennessee, United States (enrolling)
• UZ Leuven Europe Leuven — Leuven, Belgium (enrolling)
• Centre Leon Berard — Lyon, France (enrolling)
• Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL) — Amsterdam, Netherlands (enrolling)
• Seoul National University Hospital — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.